Clinical Trials Logo

Chronic Disease clinical trials

View clinical trials related to Chronic Disease.

Filter by:

NCT ID: NCT02172547 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Effect of Spiriva® on Health-related Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients Who Stopped Smoking During Treatment.

Start date: April 2006
Phase: N/A
Study type: Observational

Post marketing Surveillance to gain insights into the effects of therapy with Spiriva® (tiotropium bromide) on health-related quality of life in COPD patients who stopped smoking during treatment and to obtain safety data regarding adverse events.

NCT ID: NCT02172521 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Effect of Spiriva® 18 Microgram on Health-related Quality of Life and Physical Functioning in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Proven Hyperinflation

Start date: January 2006
Phase: Phase 4
Study type: Observational

- Primary objective of this observational study was to gain insights into the effects of therapy with Spiriva® (tiotropium bromide) 18 microgram on the health-related quality of life and physical functioning in patients with chronic obstructive pulmonary disease (COPD) and demonstrated hyperinflation. - Secondary objective was to obtain safety data regarding adverse events.

NCT ID: NCT02172508 Terminated - Clinical trials for Pulmonary Disease, Chronic Obstructive

Effect of Tiotropium Inhalation Capsules on Exercise Tolerance, Daily Activity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 3 Weeks of Pulmonary Rehabilitation

Start date: January 2004
Phase: Phase 4
Study type: Interventional

The primary objective of the study is to investigate the effect of the combined therapy 18 μg tiotropium q.d. plus pulmonary rehabilitation versus placebo plus pulmonary rehabilitation on 6-minute walking distance (6MWD) after 7 weeks of treatment in patients with moderate to severe COPD. The secondary objective of the study includes assessments of the effects of the combined therapy 18 μg Tiotropium q.d. plus rehabilitation versus placebo plus rehabilitation on dyspnoea, constant work rate exercise endurance, daily activity and lung volumes. The third objective of the study is to investigate the correlation between the results of the 6-minute walking test (6MWT), the constant work rate exercise test (CWR) and daily activity.

NCT ID: NCT02172495 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Daily Practice

Start date: June 2002
Phase:
Study type: Observational

Post-marketing surveillance to gather information regarding the tolerance and efficacy of Spiriva® 18 micrograms in patients with COPD under conditions of daily practice.

NCT ID: NCT02172482 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Start date: June 2002
Phase: N/A
Study type: Observational

As part of the post-marketing surveillance, information is to be gathered regarding the tolerance and efficacy of Spiriva® 18 micrograms in patients with COPD under conditions of daily practice

NCT ID: NCT02172469 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Efficacy and Safety of Tiotropium and Atrovent in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Start date: May 2001
Phase: Phase 3
Study type: Interventional

To compare the bronchodilator efficacy and safety of tiotropium inhalation capsules (18 µg once daily) and Atrovent® MDI (2 puffs of 20µg q.i.d.) among Filipino patients with COPD

NCT ID: NCT02172456 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Evaluation of the Lung Deposition Rate and Distribution Pattern of Tiotropium Via HandiHalerTM in Healthy Subjects and Patients With Chronic Obstructive Pulmonary Disease (COPD)

Start date: May 2002
Phase: Phase 3
Study type: Interventional

Primary endpoint: whole lung deposition and in-vivo distribution pattern of a 99mTc-labelled tiotropium powder formulation following inhalation via HandiHalerTM in healthy subjects as well as in patients with mild, moderate and severe COPD Secondary endpoints: pharmacokinetics, pharmacodynamics (effect on lung function), safety and tolerability

NCT ID: NCT02172443 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Comparison of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (MDI) in a Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease

Start date: June 2001
Phase: Phase 3
Study type: Interventional

The objective of this study is to compare the bronchodilator efficacy and safety of tiotropium inhalation capsule (18 mcg once daily) and Atrovent MDI (2 puffs of 20 mcg q.i.d.) in patients with chronic obstructive pulmonary disease (COPD)

NCT ID: NCT02172430 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Comparison of Tiotropium Inhalation Capsules and Oxitropium Metered Dose Inhalator (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Start date: September 2000
Phase: Phase 3
Study type: Interventional

The objective of this study is to investigate the long-term safety of Ba 79 BR (tiotropium) powder inhalation in patients with COPD using oxitropium bromide (Tersigan) as a comparator. Secondarily, the long-term efficacy of Ba 679 BR is also investigated

NCT ID: NCT02172404 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

HandiHaler® vs. Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Start date: October 2000
Phase: Phase 3
Study type: Interventional

Trial to compare the administration technique for HandiHaler® vs. MDI, to compare the learning retention of the administration technique for the HandiHaler® vs. MDI and to compare the ease of use for HandiHaler® vs. MDI